Healthcare provider profile · identity verified

Peter T Kim, MD

Internal Medicine · TUBA CITY, AZ · NPI 1770510984

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	861	108
Lisinopril	Lisinopril	584	71
Jardiance	Empagliflozin	397	57
Tamsulosin Hcl	Tamsulosin Hcl	344	40
Metformin Hcl	Metformin Hcl	315	39
Losartan Potassium	Losartan Potassium	288	33
Metformin Hcl Er	Metformin Hcl	275	39
Metoprolol Succinate	Metoprolol Succinate	262	30
Amlodipine Besylate	Amlodipine Besylate	228	32
Levothyroxine Sodium	Levothyroxine Sodium	228	29
Ozempic	Semaglutide	220	32
Gabapentin	Gabapentin	202	27
Omeprazole	Omeprazole	127	20
Finasteride	Finasteride	125	17
Glipizide	Glipizide	111	18
Alcohol Swabs	Alcohol Antiseptic Pads	108	38
Albuterol Sulfate Hfa	Albuterol Sulfate	92	15
Ibuprofen	Ibuprofen	71	14
Glipizide Er	Glipizide	70	suppressed
Alendronate Sodium	Alendronate Sodium	68	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	68	suppressed
Furosemide	Furosemide	67	11
Fluticasone Propionate	Fluticasone Propionate	65	17
Carvedilol	Carvedilol	61	12
Clopidogrel	Clopidogrel Bisulfate	61	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	61	22
Atenolol	Atenolol	59	suppressed
Spironolactone	Spironolactone	53	suppressed
Diclofenac Sodium	Diclofenac Sodium	51	16
Escitalopram Oxalate	Escitalopram Oxalate	50	suppressed
Novolog Flexpen	Insulin Aspart	40	15
Pantoprazole Sodium	Pantoprazole Sodium	38	suppressed
Donepezil Hcl	Donepezil Hcl	31	suppressed
Prednisone	Prednisone	30	suppressed
Eliquis	Apixaban	29	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	26	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	25	13
Montelukast Sodium	Montelukast Sodium	25	suppressed
Baclofen	Baclofen	24	suppressed
Terazosin Hcl	Terazosin Hcl	24	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	23	suppressed
Westab Plus	Pnv,calcium 72/Iron/Folic Acid	23	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	22	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	22	suppressed
Lidocaine	Lidocaine	22	suppressed
Atorvastatin Calcium	Atorvastatin Calcium	21	13
Mycophenolate Mofetil	Mycophenolate Mofetil	21	suppressed
Potassium Chloride	Potassium Chloride	21	suppressed
Duloxetine Hcl	Duloxetine Hcl	20	suppressed
Enbrel	Etanercept	20	suppressed
Humulin R U-500 Kwikpen	Insulin Regular, Human	20	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	19	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Synthroid	Levothyroxine Sodium	19	suppressed
Methotrexate	Methotrexate Sodium	17	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	16	14
Pregabalin	Pregabalin	16	suppressed
Lamotrigine	Lamotrigine	15	suppressed
Trazodone Hcl	Trazodone Hcl	15	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	13	suppressed
Famotidine	Famotidine	13	suppressed
Lactulose	Lactulose	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Dupixent Syringe	Dupilumab	12	suppressed
Haloperidol	Haloperidol	12	suppressed
Meloxicam	Meloxicam	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Pyridostigmine Bromide	Pyridostigmine Bromide	12	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	11	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Spiriva Respimat	Tiotropium Bromide	11	suppressed
Tamoxifen Citrate	Tamoxifen Citrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error